Capricor Therapeutics Stock Surges 10.5% on Duchenne Data
Capricor Therapeutics (CAPR) shares climbed 10.5% after investors focused on two-year follow-up data for its Duchenne muscular dystrophy therapy, deramiocel, presented at the World Muscle Society congress in Japan.
5% on Wednesday as investors focused on the two-year HOPE-3 follow-up data on deramiocel, the company’s intravenous cell therapy for Duchenne muscular dystrophy, now circulating as a poster at the World Muscle Society congress in Hiroshima. m. local time.